Publication | Closed Access

Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors

MedicineImmunologyPathologyCell DeathBronchial NeoplasmTyrosine Kinase InhibitorsClinical OutcomesImmune Checkpoint InhibitorCancer TreatmentLung CancerOncologyDeath-ligand 1Tumor MicroenvironmentCancer Research